These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 3622304)

  • 41. Cyclandelate: calcium modulation and clinical effects. Proceedings of a symposium. Helsinki, 14-15 November, 1986.
    Drugs; 1987; 33 Suppl 2():1-141. PubMed ID: 3622302
    [No Abstract]   [Full Text] [Related]  

  • 42. Cyclandelate in the management of tinnitus: a randomized, placebo-controlled study.
    Hester TO; Theilman G; Green W; Jones RO
    Otolaryngol Head Neck Surg; 1998 Mar; 118(3 Pt 1):329-32. PubMed ID: 9527112
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect of cyclandelate on mental function in patients with arteriosclerotic brain disease.
    Fine EW; Lewis D; Villa-Landa I; Blakemore CB
    Br J Psychiatry; 1970 Aug; 117(537):157-61. PubMed ID: 4921174
    [No Abstract]   [Full Text] [Related]  

  • 44. A pilot study to evaluate the effect of acute and long-term administration of cyclandelate on the vigilance of subjects submitted to hypoxic conditions. Preliminary report.
    Schaffler K; Hörmann E; Arnold H
    Arzneimittelforschung; 1981; 31(6):1032-5. PubMed ID: 7196236
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Modes and mechanisms of action of vasoactive drugs and especially of cyclandelate.
    Timmerman H
    Br J Clin Pract Suppl; 1984; 34():10-9. PubMed ID: 6430317
    [No Abstract]   [Full Text] [Related]  

  • 46. Effect of tinofedrine (Homburg D8955) on cerebral blood flow in multi-infarct dementia.
    Merory J; Du Boulay GH; Marshall J; Morris J; Russell RW; Symon L; Thomas DJ
    J Neurol Neurosurg Psychiatry; 1978 Oct; 41(10):900-2. PubMed ID: 731238
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cyclandelate versus propranolol in the prophylaxis of migraine--a double-blind placebo-controlled study.
    Gerber WD; Schellenberg R; Thom M; Haufe C; Bölsche F; Wedekind W; Niederberger U; Soyka D
    Funct Neurol; 1995; 10(1):27-35. PubMed ID: 7649498
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Drugs for dementia.
    Drug Ther Bull; 1975 Oct; 13(22):85-7. PubMed ID: 1102280
    [No Abstract]   [Full Text] [Related]  

  • 49. Ginkgo biloba special extract in dementia with neuropsychiatric features. A randomised, placebo-controlled, double-blind clinical trial.
    Napryeyenko O; Borzenko I;
    Arzneimittelforschung; 2007; 57(1):4-11. PubMed ID: 17341003
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fibrinolytic activity of oral cyclandelate in patients with generalized atherosclerotic vasculopathy: a double-blind study.
    Forconi S; Cappelli R; Guerrini M; Frigerio C; Messa GL; Furesi L
    J Int Med Res; 1990; 18(4):257-65. PubMed ID: 2121564
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Idebenone in the treatment of multi-infarct dementia: a randomised, double-blind, placebo controlled multicentre trial.
    Bergamasco B; Villardita C; Coppi R
    Arch Gerontol Geriatr; 1992; 15(3):271-8. PubMed ID: 15374366
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cyclandelate and mental functions: a double-blind cross-over trial in normal elderly subjects.
    Judge TG; Urquhart A; Blakemore CB
    Age Ageing; 1973 May; 2(2):121-4. PubMed ID: 4591604
    [No Abstract]   [Full Text] [Related]  

  • 53. Efficacy and tolerance of cyclandelate versus pizotifen in the prophylaxis of migraine.
    Mastrosimone F; Iaccarino C; de Caterina G
    J Med; 1992; 23(1):1-16. PubMed ID: 1573338
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Letter: Cyclandelate and improved brain function.
    Wechsler AF
    Am J Psychiatry; 1974 Jun; 131(6):723. PubMed ID: 4827806
    [No Abstract]   [Full Text] [Related]  

  • 55. WAIS testing in degenerative and multi-infarct dementia.
    Gandolfo C; Vecchia R; Moretti C; Brusa G; Scotto PA
    Acta Neurol (Napoli); 1986 Feb; 8(1):45-50. PubMed ID: 3962755
    [No Abstract]   [Full Text] [Related]  

  • 56. Drug therapy: cerebral vasodilators (first of two parts).
    Cook P; James I
    N Engl J Med; 1981 Dec; 305(25):1508-13. PubMed ID: 7029283
    [No Abstract]   [Full Text] [Related]  

  • 57. Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study.
    Görtelmeyer R; Erbler H
    Arzneimittelforschung; 1992 Jul; 42(7):904-13. PubMed ID: 1418054
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effects of cyclandelate on psychological test performance in patients with cerebral vascular insufficiency.
    Smith WL; Lowrey JB; Davis JA
    Curr Ther Res Clin Exp; 1968 Dec; 10(12):613-8. PubMed ID: 4972756
    [No Abstract]   [Full Text] [Related]  

  • 59. Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial.
    Ihl R; Bachinskaya N; Korczyn AD; Vakhapova V; Tribanek M; Hoerr R; Napryeyenko O;
    Int J Geriatr Psychiatry; 2011 Nov; 26(11):1186-94. PubMed ID: 21140383
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ginkgo biloba extract EGb 761 in dementia: intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial.
    Kanowski S; Hoerr R
    Pharmacopsychiatry; 2003 Nov; 36(6):297-303. PubMed ID: 14663654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.